| HIV Infections

Reyataz vs Prezista

Side-by-side clinical, coverage, and cost comparison for hiv infections.

Deep comparison between: Reyataz vs Prezista with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsPrezista has a higher rate of injection site reactions vs Reyataz based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Prezista but not Reyataz, including UnitedHealthcare

Category

Reyataz

Prezista

At A Glance

RouteOral

FrequencyOnce daily

ClassHIV-1 protease inhibitor

RouteOral

FrequencyOnce daily or Twice daily

ClassHIV-1 protease inhibitor

Indications

HIV Infections

HIV Infections

Dosing

HIV Infections (treatment-naive adults) 300 mg once daily with ritonavir 100 mg once daily with food, or 400 mg once daily with food if unable to tolerate ritonavir

HIV Infections (treatment-experienced adults) 300 mg once daily with ritonavir 100 mg once daily with food; 400 mg once daily with ritonavir 100 mg once daily if taken with both tenofovir DF and H2-receptor antagonist

HIV Infections (pediatric patients 6 to less than 18 years, 15 to less than 35 kg) 200 mg once daily with ritonavir 100 mg once daily with food

HIV Infections (pediatric patients at least 35 kg) 300 mg once daily with ritonavir 100 mg once daily with food

HIV Infections (pediatric patients at least 3 months, 5 to less than 15 kg) 200 mg oral powder once daily with ritonavir 80 mg once daily with food

HIV Infections (pregnant patients) 300 mg once daily with ritonavir 100 mg once daily with food; 400 mg once daily with ritonavir 100 mg once daily during second or third trimester when coadministered with either H2-receptor antagonist or tenofovir DF

HIV-1 Infections (treatment-naive adults) Darunavir 800 mg with ritonavir 100 mg once daily, oral, with food

HIV-1 Infections (treatment-experienced adults, no darunavir resistance) Darunavir 800 mg with ritonavir 100 mg once daily, oral, with food

HIV-1 Infections (treatment-experienced adults, at least one darunavir resistance substitution) Darunavir 600 mg with ritonavir 100 mg twice daily, oral, with food

HIV-1 Infections (pregnant patients) Darunavir 600 mg with ritonavir 100 mg twice daily, oral, with food

HIV-1 Infections (pediatric patients, 3 to less than 18 years) Weight-based dosing with ritonavir, oral, with food. Dosage based on body weight and resistance status, not to exceed adult dose

Contraindications

Previously demonstrated clinically significant hypersensitivity (eg, Stevens-Johnson syndrome, erythema multiforme, toxic skin eruptions) to any component
Coadministration with drugs highly dependent on CYP3A or UGT1A1 for clearance where elevated plasma concentrations are associated with serious or life-threatening events (alfuzosin, cisapride, pimozide, orally administered midazolam, triazolam, ergot derivatives, lovastatin, simvastatin, lomitapide, sildenafil for pulmonary arterial hypertension, indinavir, irinotecan, lurasidone when boosted with ritonavir, apalutamide, encorafenib, ivosidenib, elbasvir/grazoprevir, glecaprevir/pibrentasvir)
Coadministration with strong CYP3A inducers (rifampin, St. John's wort, carbamazepine, phenobarbital, phenytoin, nevirapine)

Co-administration with alfuzosin
Co-administration with colchicine in patients with renal and/or hepatic impairment
Co-administration with rifampin
Co-administration with lurasidone
Co-administration with pimozide
Co-administration with dronedarone
Co-administration with ivabradine
Co-administration with ranolazine
Co-administration with ergot derivatives (dihydroergotamine, ergotamine, methylergonovine)
Co-administration with St. John's wort (Hypericum perforatum)
Co-administration with elbasvir/grazoprevir
Co-administration with lomitapide
Co-administration with lovastatin
Co-administration with simvastatin
Co-administration with naloxegol
Co-administration with sildenafil for pulmonary arterial hypertension
Co-administration with orally administered midazolam
Co-administration with triazolam

Drug Interactions

1374View drug interactions

1172View drug interactions

Adverse Reactions

Most common (>=2%) Nausea, jaundice/scleral icterus, rash, headache, insomnia, dizziness, vomiting, abdominal pain, diarrhea, fever, myalgia, depression, peripheral neurologic symptoms

Serious Cardiac conduction abnormalities (PR interval prolongation, second-degree AV block, third-degree AV block), chronic kidney disease, nephrolithiasis, cholelithiasis

Postmarketing Edema, QTc prolongation, left bundle branch block, pancreatitis, hepatic function abnormalities, cholecystitis, cholestasis, diabetes mellitus, hyperglycemia, arthralgia, interstitial nephritis, granulomatous interstitial nephritis, alopecia, maculopapular rash, pruritus, angioedema

Most common (>=5%, treatment-naive) Diarrhea, headache, abdominal pain, rash, nausea, vomiting

Most common (>=5%, treatment-experienced) Diarrhea, nausea, rash, abdominal pain, vomiting

Serious Hepatotoxicity, severe skin reactions (Stevens-Johnson Syndrome, toxic epidermal necrolysis), acute pancreatitis, diabetes mellitus, hyperglycemia, immune reconstitution syndrome

Postmarketing Rhabdomyolysis, acute generalized exanthematous pustulosis, drug rash with eosinophilia and systemic symptoms, crystal nephropathy, crystalluria

Pharmacology

Atazanavir is an azapeptide HIV-1 protease inhibitor that selectively inhibits virus-specific processing of viral Gag and Gag-Pol polyproteins in HIV-1-infected cells, preventing formation of mature virions.

Darunavir is an HIV-1 protease inhibitor that selectively inhibits cleavage of HIV-1 Gag-Pol polyproteins in infected cells, preventing formation of mature virus particles.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Reyataz